RSV Vaccination 2024: What Payers Need to Know for Effective Coverage

Payers Can Optimize Health Outcomes and Cost Management for RSV Vaccination Coverage by Understanding Several Considerations

With all the focus on flu and COVID-19 in recent years, it is easy to overlook another respiratory threat: Respiratory Syncytial Virus (RSV). As the third most common viral cause of hospitalization, RSV follows a similar seasonal pattern to the flu, from October to April. While RSV often shows mild cold-like symptoms in most people, it can lead to severe complications, particularly in vulnerable populations. As we enter a new era of RSV prevention with recently approved vaccines, it’s important to understand the impact of this virus, the options now available to combat it, and the considerations for its coverage.

Understanding RSV: More Than Just a Common Cold

RSV is a highly contagious virus spread through coughing, sneezing, and direct contact like shaking hands. For many, it causes typical cold symptoms such as a runny nose, cough, sore throat, sneezing, headache, and fever, which are usually resolved within 1-2 weeks. However, RSV can escalate to more severe infections, including pneumonia and bronchiolitis – an inflammation of the small airways in the lungs. Notably, RSV is the leading cause of these lung conditions in infants under one year old.

The Adult Impact: Who’s at Highest Risk?

While often associated with pediatric cases, RSV poses significant risks to certain adult populations:

• Individuals 75 and older
• Individuals 60 and older with immunosuppressed or comorbid lung or heart conditions
• Residents of long-term care facilities

These groups face the highest risk of RSV-related hospitalization, underscoring the importance of preventive measures.

A New Era of Prevention: RSV Vaccine Options

The landscape of RSV prevention changed dramatically in 2023 with the introduction of vaccines for adults as well as the vaccine, Beyfortus, for the pediatric population. All adult vaccines are approved for preventing lower respiratory tract disease (LRTD) in individuals 60 and above:

1. Abrysvo
   • Additional indication for use during pregnancy (32-36 weeks) to protect newborns
   • Milder side effect profile including primarily fatigue, headache, and injection site pain
2. Arexvy
   • Additional indication for at-risk adults aged 50-59, though the age group is not currently endorsed by CDC recommendations
   • Common side effects include injection site pain, fatigue, and myalgia (body aches)
3. mResvia (approved May 2024)
   • Newest option, an mRNA vaccine
   • Side effects similar to other options, with potential for lymph node swelling like COVID-19 mRNA vaccines

All three vaccines demonstrate similar effectiveness (80-85%) and cost (approximately $325), with higher efficacy in the 70+ population.

CDC Recommendations: Navigating the New Guidelines

On June 24, 2024, the CDC’s Advisory Committee on Immunization Practices (ACIP) released updated recommendations for RSV vaccination in adults:

• All adults 75 years or older should receive the vaccine
• Adults 60-74 with risk factors (chronic lung/heart disease, nursing home residency, immunocompromised, obesity, or diabetes) are recommended for vaccination
• Eligible individuals who missed vaccination last year should receive it in late summer or early fall (August to October)
• RSV vaccination is currently recommended once per lifetime, not annually
• It can be given concurrently with flu and/or COVID-19 vaccines

Optimizing RSV Management: Considerations For Payers

As the RSV vaccination landscape evolves, payers and plan sponsors face several key considerations. When discussing coverage, implementing appropriate utilization management protocols is crucial to ensure access for those who need the vaccine most while managing costs effectively. Understanding the potential impact of RSV and other vaccines on plan spend and trend in 2024 and beyond is essential for effective budget management. Payers should conduct thorough analyses to project costs and potential savings from reduced hospitalizations. It is also important to stay informed about new recommendations for RSV and other vaccinations.

By leveraging expert guidance and taking a proactive approach to RSV prevention, payers can play a vital role in balancing member health needs with financial sustainability. As we continue to navigate the complex world of respiratory viruses, staying apprised and adaptable will be key to effective benefit management strategies. Connect with a PSG expert to learn more about optimizing your approach to RSV prevention and overall vaccine management.